Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Lung Neoplasms 8Hematologic Neoplasms 5Colorectal Neoplasms 5Prostatic Neoplasms 4Hodgkin Disease 4Carcinoma, Non-Small-Cell Lung 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Motor Activity 3Pancreatic Neoplasms 2Obesity 2Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Hematopoietic and Lymphoid System Neoplasm 2Gastrointestinal Diseases 2Cardiotoxicity 2Urinary Bladder Neoplasms 1Trastuzumab Cardiotoxicity 1Small Cell Lung Carcinoma 1Sedentary Behavior 1Sarcopenia 1Polycystic Ovary Syndrome 1Pelvic Neoplasms 1Pathologically Proven Gastrointestinal Malignancy 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Myocardial Fibrosis 1Myelodysplastic Syndromes 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Exercise Test 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Trastuzumab Cardiotoxicity × Exercise Test × Clear all
NCT02615054 2024-04-11

Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

Memorial Sloan Kettering Cancer Center

Completed
58 enrolled
Breast

Trastuzumab Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡